MS News that Caught My Eye Last Week: MS Biomarker, Best RRMS Early Treatment, Ocrevus Study, Out-of-Pocket Costs
#AANAM – Biogen Offers Update on Development Plans for MS Therapies The pharma company that brought you Tysabri (natalizumab) is investigating a new process for treating multiple sclerosis. The treatment looks for something called neurofilament light chain (NfL), a potential biomarker that’s released from damaged neurons.